Showing posts with label China. Show all posts
Showing posts with label China. Show all posts

Saturday, 7 September 2013

Apple faces threat from China, bellwether in battle against Android

Computerworld - Apple faces a threat from an unexpected quarter: Chinese developers crafting Android apps, an analytics firm said today.

Chinese developers build nearly two-thirds of the mobile apps used by Chinese consumers -- an even higher percentage than U.S. developers contribute to U.S. consumers' app usage patterns -- illustrating not only the difficulty outsiders face in breaking into the massive market, but reinforcing one analyst's claim that Apple will face a crisis next year if it continues to shed smartphone share.

According to Flurry, a U.S.-based mobile analytics firm, U.S. developers are losing their grip on the mobile app ecosystem, and have accounted for just 36% of all smartphone and tablet apps published so far this year. That's down from 45% over the last two years.

The U.S.'s contribution to the overall app market -- Android and iOS -- looked better when Flurry weighted the data by time spent with apps: There, U.S. developers accounted for 70%. But that, too, was smaller than in years prior, when U.S. programmers held app usage shares of 75% and 76% in 2011 and 2012, respectively.

While Flurry's data was meant to push U.S. developers to think globally -- something they've not done nearly as successfully as those in other countries -- it also revealed an interesting trend in China.

China, said Simon Khalaf, president and CEO of Flurry, is not a big software exporter at the moment. But that will change.

"The software export market [for China] is nascent now, it doesn't look like a big software exporter yet," said Khalaf in an interview. "But Chinese developers are starting to see some adoption in Japan and Korea. That's their focus now: CJK [China, Japan and Korea]."

And Chinese apps, localized for export, will continue to grab global share by expanding into other neighboring markets, including Southeast Asia, India and Indonesia. "The sheer numbers in India ... that's a lot of market [for Chinese apps]," said Khalaf.

The Chinese maneuver may seem inconsequential to Apple at first glance, but Khalaf begged to differ.

That's because Chinese consumers are more likely to be using an Android-based smartphone, one tied to the Android ecosystem, than they are to own an iPhone and rely on Apple's app market. In earlier studies by Flurry, the firm pegged the Android-iOS split in China at about 2 to 1, with Apple's installed base accounting for just 35% of the country's total. The remaining was all Android.

And Chinese developers, like all developers, follow the money. If Android dominates the installed base, Android is what developers will write for.

"When you look at the apps being submitted to Flurry, you do see an interesting shift happening, with Chinese developers releasing Android and iOS apps at the same time," said Khalaf. "But an 'Android-first' release could be the next shift down the road."

And that's where things start to get ugly for Apple. Or so Benedict Evans, an analyst with U.K.-based Enders Analysis, has argued.

In a report published in early August, Evans maintained that without a low-priced iPhone in its portfolio -- and by low, he meant as low as $200 to $300 -- Apple risked losing mind share among developers. In other words, Apple needs market share as much as profit margin for the iPhone to continue being a credible smartphone brand.

Like Khalaf, Evans saw the danger stemming from developers' decisions.

"Developers are starting to move from creating new products on the basis 'iPhone, then maybe Android' to 'iPhone and then Android' or even 'iPhone and Android at the same time,'" Evans said in his report. "We do not see Android becoming a first choice this year, but it is no longer optional for any publisher seeking real reach. If total Android engagement moves decisively above iOS, the fact that iOS will remain big will be beside the point -- it will move from first to first-equal and then perhaps second place on the roadmap."

If that happens, Apple is in a world of hurt.

How Cloud Communications Reduce Costs and Increase ProductivitySmall and midsize businesses are moving to the cloud to host their communications capabilities. Learn how enterprise-quality phone benefits, online management, conferencing, auto attendant, and ease of use are built into a system that is half the cost of a PBX.

Read now.


View the original article here

Sunday, 11 August 2013

China Biotech In Review: Fundings For China-Affiliated Drug Companies

Deals and Financings

Shenogen Pharma of Beijing raised $20 million in a series C funding, which the company will use to support a Phase II trial of its lead drug candidate, icaritin, a small molecule drug that targets the estrogen receptor alpha 36. The trial will enroll patients with hepatocellular cancer. The drug is derived from barrenwort, a TCM. The funding was led by Legend Capital and Qiming Weichuang Venture Capital. Investors also received warrants to buy an additional $10 million in shares.

Apexigen, a California antibody company with strong connections to several China pharmas, brought in $20 million in a Series A1 financing. Apexigen was originally the drug development arm of Epitomics, a company built around a rabbit-based platform for developing monoclonal antibodies. Two China companies - Simcere (NYSE: SCR) and 3SBio (NSDQ: SSRX) - have filed with the CFDA to begin clinical trials of Apexigen-discovered drugs.

Zhongyuan Union Stem Cell Bioengineering (SHA: 600645) formed a stem cell JV with Cell Therapy Ltd. of Wales. The JV will focus on developing stem cell therapies for major diseases such as heart disease and diabetes, presumably based on CTL's technology. It plans to build two operational hubs near Shanghai and Beijing, with smaller offices in other China cities. The two firms will share the JV's China revenues equally, while Cell Therapy will have first option on Zhongyuan Union's products outside China.

Sinopharm Group will build a China Biotechnology Research Institute in Wuhan East Lake High-tech Zone, gathering together its existing biotech R&D resources into one location. The facility will be part of a Sinopharm subsidiary, the China Institute of Pharmaceutical Industry. Sinopharm says the Institute will be the largest biotech R&D operation in China, comprising two to three separate buildings. Construction will take three years.

ScinoPharm (TAI: 1789), a Taiwan CRO with expertise in process development and generic API production, formed a strategic alliance with Sundia MediTech Company, the Shanghai CRO. The two companies will collaborate to provide Contract Research and Manufacturing Services (CRAMS) in China. ScinoPharma will participate through its China subsidiary, ScinoPharm Changshu.

Mitsubishi Tanabe Pharma will spend $19.5 million to build a new China production facility in Tianjin. The plant will be owned by Tianjin Tanabe Seiyaku, a joint venture in which Mitsubishi holds a 75% stake. Its local partner, Tianjin Lisheng Pharmaceutical Co., owns the remaining 25%. The new facility will be built on the JV's existing site in the Tianjin Economic Development Area.

Komtur Pharmaceuticals, a German clinical trial sourcing company, set up a China JV with HengHeKangJian Pharmaceutical. The JV will build a state-of-the-art distribution center that is compliant with the latest China and international standards. It will offer distribution of clinical trial supplies and sourcing of reference drugs. The JV will also provide commercial distribution of finished pharmaceuticals and medical devices, and will eventually move into pharmaceutical labeling and re-packaging.

Allium Medical ((TASE: ALMD)) of Israel signed up Beijing King Health Investment to distribute the company's urinary tract stents in China. King Health agreed to buy at least $16 million of Allium's stents during the eight-year run of the contract. The two companies expect to launch the urinary stents in 2016, assuming CFDA approval.

Trials and Approvals

A JV consisting of Zoetis (NYSE: ZTS), the recently spun-off animal health subsidiary of Pfizer (NYSE: PFE), and Jilin Guoyuan Animal Health Co. has received marketing approval in China for a new swine vaccine (see story). Rui Lan An™ targets highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS). The JV, which was announced in 2011, will launch the vaccine immediately. Zoetis/Pfizer and Jilin Guoyuan formed the JV to meet the needs of China's livestock producers, particularly the pork industry.

Company News

According to press reports, Sanofi (NYSE: SNY) paid China doctors kickbacks to prescribe its blood pressure drugs (see story). An anonymous whistleblower alleged that the company's representatives paid 1.7 million RMB ($280,000) to over 500 doctors in 79 hospitals - about $500 each. The illegal payments, which were made in November 2007, were billed as research fees or grants, said the whistleblower.

Disclosure: none.


View the original article here